The first Middle East and North Africa expert consensus recommendations for the management of advanced colorectal cancer

Abstract

Colorectal cancer (CRC) is ranked as the third most prevalent and the second deadliest cancer worldwide. In the Middle East and North Africa (MENA) region, the number of CRC cases increased over the past decades and will nearly double by 2030. The lack of clear MENA guidelines for the management of patients with CRC represents a step backwards in the fight against this burden. Therefore a panel of 24 MENA experts in the field of gastrointestinal oncology developed, using a Delphi process, the first consensus recommendations for the management of patients with advanced CRC. Forty-seven different statements were formulated in the areas of epidemiology, screening, biomarkers and treatment. These recommendations will guide, standardize and unify the management of this cancer in the MENA region. © 2022 Future Medicine Ltd.

Description

Keywords

Clinical practice guidelines, Colorectal cancer, Consensus, Mena, Africa, northern, Colorectal neoplasms, Humans, Medical oncology, Middle east, Aflibercept, Angiogenesis inhibitor, Antineoplastic agent, B raf kinase, Bevacizumab, Binimetinib, Biological product, Cetuximab, Deruxtecan, Encorafenib, Entrectinib, Fluoropyrimidine, Fluorouracil, Folinic acid, Immune checkpoint inhibitor, Ipilimumab, Irinotecan, Lapatinib, Larotrectinib, Nivolumab, Oxaliplatin, Panitumumab, Pembrolizumab, Pertuzumab, Ramucirumab, Tumor marker, Article, Braf gene, Cancer localization, Cancer therapy, Cytoreductive surgery, Delphi study, Diagnostic test, Disease management, Disease marker, Epidemiological data, Gastrointestinal oncology, Gene mutation, Human, Induction chemotherapy, Liquid biopsy, Medical expert, Microsatellite instability, Mismatch repair, Molecular diagnosis, Molecularly targeted therapy, North africa, Oncogene ras, Oncology, Screening, Treatment indication, Africa, Colorectal tumor

Citation

Endorsement

Review

Supplemented By

Referenced By